PFE - Pfizer Inc. | StockAlert.pro

Stock Details

Pfizer Inc. (PFE), a prominent company in the life sciences sector within the pharmaceutical preparations industry, is based in USA and primarily trades on the NYSE.Currently, the stock is trading at $24.81. Over the past 52 weeks, it has ranged between $20.18 and $29.47. This places the current price at 84.2% of its 52-week high and 22.9% above its 52-week low. Recent trading volume was recorded at 35,544,848. The International Securities Identification Number (ISIN) for this stock is US7170811035.

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

17.53

Near market average

Forward P/E

8.29

Earnings expected to grow

PEG Ratio

0.61

Potentially undervalued

Price to Book

1.52

EV/EBITDA

10.53

EPS (TTM)

$1.38

Price to Sales

2.20

Beta

0.49

Less volatile than market

How is PFE valued relative to its earnings and growth?

Pfizer Inc. trades at a P/E ratio of 17.53, which is near the market average of approximately 20, suggesting the market views it as fairly valued relative to its earnings. Looking ahead, the forward P/E of 8.29 is lower than the current P/E, indicating analysts expect earnings to grow over the next year. The PEG ratio of 0.61 suggests the stock may be undervalued relative to its growth rate.

What is PFE's risk profile compared to the market?

With a beta of 0.49, Pfizer Inc. is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 1.52 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

12.60%

Operating Margin

35.20%

Return on Equity

8.62%

Return on Assets

4.79%

Revenue Growth (YoY)

-7.80%

Earnings Growth (YoY)

-5.30%

How profitable and efficient is PFE's business model?

Pfizer Inc. achieves a profit margin of 12.60%, meaning it retains $12.60 from every $100 in revenue after all expenses. This represents a solid margin typical of well-run businesses, showing the company can effectively balance revenue generation with cost control. The operating margin of 35.20% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at 8.62% and ROA at 4.79%, the company achieves moderate returns on invested capital.

What are PFE's recent growth trends?

Pfizer Inc.'s revenue declined by 7.80% year-over-year, indicating challenges in maintaining sales momentum. This contraction may reflect market headwinds, competitive pressures, or strategic transitions. Earnings decreased by 5.30% year-over-year, outpacing revenue growth through improved margins. These growth metrics should be evaluated against PHARMACEUTICAL PREPARATIONS industry averages for proper context.

Dividend Information

Dividend Per Share

$1.69

Dividend Yield

7.11%

Ex-Dividend Date

7/25/2025

Dividend Date

9/2/2025

What dividend income can investors expect from PFE?

Pfizer Inc. offers a dividend yield of 7.11%, paying $1.69 per share annually. This high yield exceeds 4%, significantly outperforming the S&P 500 average of 1.5-2% and most investment-grade bonds. For income-focused investors, this represents an attractive cash flow opportunity, though high yields sometimes signal market concerns about sustainability. To receive the next dividend, shares must be purchased before the ex-dividend date of 7/25/2025.

How reliable is PFE's dividend for long-term investors?

The dividend sustainability can be assessed through the payout ratio - Pfizer Inc. pays $1.69 per share in dividends against earnings of $1.38 per share, resulting in a payout ratio of 100.00%. This very high payout exceeding 90% raises sustainability concerns, as nearly all earnings go to dividends. Any earnings decline could force a dividend cut. The next dividend payment is scheduled for 9/2/2025.

Company Size & Market

Shares Outstanding

5.69B

Book Value/Share

$15.89

Asset Type

Common Stock

What is PFE's market capitalization and position?

Pfizer Inc. has a market capitalization of $137.53B, classifying it as a large-cap stock ($10B-$200B). Large-caps are typically industry leaders with established business models, offering a balance of stability and growth potential. They often provide dividend income and are core holdings in institutional portfolios. With 5.69B shares outstanding, the company's ownership is widely distributed. As a major player in the PHARMACEUTICAL PREPARATIONS industry, it competes with other firms in this sector.

How does PFE's price compare to its book value?

Pfizer Inc.'s book value per share is $15.89, while the current stock price is $24.81, resulting in a price-to-book (P/B) ratio of 1.56. This reasonable premium to book value suggests the market values the company's earnings power and intangible assets appropriately. Most profitable companies trade between 1-3x book value. As a common stock, this represents equity ownership with voting rights.

Analyst Ratings

Analyst Target Price

$29.24

17.86% upside potential

Analyst Recommendations

Strong Buy

Buy

Hold

Sell

Strong Sell

How reliable are analyst predictions for PFE?

25 analysts cover PFE with 36% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The mixed views reflect uncertainty about the outlook. The consensus target of $29.24 implies 17.9% upside, but targets are often adjusted to follow price moves rather than predict them.

What is the Wall Street consensus on PFE?

Current analyst recommendations:2 Strong Buy, 7 Buy, 15 Hold, 1 Sell, 0The neutral stance suggests uncertainty or fair valuation at current levels.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Jul 1, 2025, 02:22 AM

Pfizer Inc. (PFE) Stock